Azerbaijani
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Efficacy Study of Adalimumab to Treat Interstitial Cystitis

Yalnız qeydiyyatdan keçmiş istifadəçilər məqalələri tərcümə edə bilərlər
Giriş / Qeydiyyatdan keçin
Bağlantı panoya saxlanılır
StatusTamamlandı
Sponsorlar
ICStudy, LLC
Əməkdaşlar
Abbott

Açar sözlər

Mücərrəd

The purpose of this study is to evaluate an investigational treatment for interstitial cystitis. Interstitial cystitis is a chronic bladder disease that includes the following symptoms: Urinary frequency during the day,urinary frequency at night, urinary urgency and bladder discomfort relieved by voiding.
Presently, there is no cure for interstitial cystitis. The response to current treatments is poor. Patients with interstitial cystitis have a poorer quality of life. The cause of interstitial cystitis is unknown. This study is evaluating the drug Humira® (adalimumab) for improving the symptoms of patients with interstitial cystitis. Humira® is an injectable anti-inflammatory medication that has been available for use since December 31, 2002. Humira® has been FDA approved for the treatment of rheumatoid arthritis, psoriasis, ankylosing spondylitis, and Crohn's disease. These diseases have similar characteristics to interstitial cystitis. This study will evaluate an investigational use of Humira® for the treatment of interstitial cystitis.

Təsvir

Interstitial cystitis (IC) is a chronic disabling bladder syndrome characterized by urinary frequency, nocturia, urinary urgency, and pain with bladder filling-relieved by emptying. There is no cure for IC and the treatment options are suboptimal. Patients with IC report significant negative effects on their physical and mental quality of life. The etiology of IC is unknown. Certain aspects of IC suggest that autoimmunity may play a role in initiating or sustaining the chronic inflammatory response. Bladder biopsies of patients with IC demonstrate an increase number of mast cells. Mast cell activation with the release of tumor necrosis factor (TNF) may mediate this bladder inflammation. Humira® (adalimumab) is a medication that blocks the effect of TNF. Humira® (adalimumab) is FDA approved for the treatment of rheumatoid arthritis, psoriasis, ankylosing spondylitis, and Crohn's disease. These diseases are similar to IC. In this study, the hypothesis being tested is that Humira® (adalimumab) will show efficacy at reducing the symptoms of IC.

Tarixlər

Son Doğrulandı: 06/30/2015
İlk təqdim: 02/13/2011
Təxmini qeydiyyat təqdim edildi: 02/13/2011
İlk Göndərmə: 02/14/2011
Son Yeniləmə Göndərildi: 07/11/2015
Son Yeniləmə Göndərildi: 07/15/2015
İlk təqdim edilmiş nəticələrin tarixi: 07/19/2013
İlk təqdim edilmiş QC nəticələrinin tarixi: 07/11/2015
İlk göndərilən nəticələrin tarixi: 07/15/2015
Həqiqi Təhsilin Başlama Tarixi: 02/28/2011
Təxmini İlkin Tamamlanma Tarixi: 05/31/2013
Təxmini İşin Tamamlanma Tarixi: 06/30/2013

Vəziyyət və ya xəstəlik

Interstitial Cystitis

Müdaxilə / müalicə

Drug: adalimumab

Other: Inactive drug

Faza

Faza 3

Qol Qrupları

QolMüdaxilə / müalicə
Experimental: adalimumab
Adalimumab 80mg subcutaneous loading dose followed by 40 mg subcutaneous every 2 weeks for 12 weeks
Drug: adalimumab
80 mg loading dose given subcutaneously followed by 40 mg dose given subcutaneously every two weeks over a twelve week period
Placebo Comparator: Inactive drug
Placebo in identical syringe subcutaneous every 2 weeks for 12 weeks
Other: Inactive drug
80 mg loading dose given subcutaneously followed by 40 mg dose given subcutaneously every two weeks over a twelve week period

Uyğunluq Kriteriyaları

Təhsil üçün uyğun yaşlar 18 Years Üçün 18 Years
Təhsilə Uyğun CinslərAll
Sağlam Könüllüləri qəbul edirBəli
Kriteriyalar

Inclusion Criteria:

- Males or females ≥18 and ≤ 65 years of age previously diagnosed with Interstitial Cystitis

- Currently have symptoms of urinary urgency, frequency or pain for more than 6 months

- Urinating at least 7 times a day or having some urgency or pain (measured on linear analog scales)

- Must be post-menopausal or surgically sterile or willing to use an adequate form of birth control

- Not pregnant or lactating

- Capable of voiding independently

- Willing to provide informed consent to participate

Exclusion Criteria:

- Have symptoms that are presently relieved on other medications for interstitial cystitis

- Have absence of nocturia

- Have symptoms that are relieved by antimicrobials or antibiotics.

- Have a body mass index (BMI) of >39 kg/m2

- Have uncontrolled hypertension

- Have Type I or type 2 diabetes

- Have active Hepatitis B, Hepatitis C, or Human Immunodeficiency Virus (HIV) infection, or who are known carriers (Hepatitis B) at Screening

- Have a positive tuberculosis test at screening

- Have had a urinary tract infection for 6 weeks

- Have had bacterial cystitis in previous 3 months

- Have had previous exposure to Humira® (adalimumab)

- Have taken investigational medication within 30 days of screening

- Have any other condition/disease which, in the opinion of the investigator, could compromise subject safety or confound the interpretation of study results

- Are unable or unwilling to comply with protocol requirements

Nəticə

İlkin nəticə tədbirləri

1. O'Leary-Santa Interstitial Cystitis Symptom Index and Problem Index (OSPI) Score [Baseline/12 Weeks]

Improvement in the O'Leary Sant Symptom and Problem Index from baseline to week 12 Total scores on a scale range: 0-36 (0, meaning no symptoms to 36, meaning the most severe symptoms)

İkincili Nəticə Tədbirləri

1. Interstitial Cystitis Symptom Index (ICSI) [Baseline/ 12 weeks]

Improvement in O'Leary Sant Interstitial Cystitis Symptom Index (ICSI) Total scores on a range scale: 0-20 (0, meaning no symptoms, to 20, meaning the most severe symptoms)

2. Interstitial Cystitis Problem Index (ICPI) [Baseline/12 Weeks]

Improvement in O'Leary Sant Interstitial Cystitis Problem Index (ICPI) Total scores on a scale: 0-16 (0, meaning no symptoms, to 16, meaning the most severe symptoms)

3. Pelvic Pain Urgency/Frequency (PUF) Score [Baseline12 Weeks]

Pelvic Pain, Urgency/Frequency Symptom Scale Total scores on a scale range: 0-35 (0, meaning no symptoms, to 35, meaning the most severe symptoms)

4. Global Response Assessment (GRA) [Measured at12 Weeks]

Percent(%) of patients who reported 50% or greater overall improvement in their condition. Score on a scale range (improvement 0%-100%)

Facebook səhifəmizə qoşulun

Elm tərəfindən dəstəklənən ən tam dərman bitkiləri bazası

  • 55 dildə işləyir
  • Elm tərəfindən dəstəklənən bitki mənşəli müalicələr
  • Təsvirə görə otların tanınması
  • İnteraktiv GPS xəritəsi - yerdəki otları etiketləyin (tezliklə)
  • Axtarışınızla əlaqəli elmi nəşrləri oxuyun
  • Təsirlərinə görə dərman bitkilərini axtarın
  • Maraqlarınızı təşkil edin və xəbər araşdırmaları, klinik sınaqlar və patentlər barədə məlumatlı olun

Bir simptom və ya bir xəstəlik yazın və kömək edə biləcək otlar haqqında oxuyun, bir ot yazın və istifadə olunan xəstəliklərə və simptomlara baxın.
* Bütün məlumatlar dərc olunmuş elmi araşdırmalara əsaslanır

Google Play badgeApp Store badge